Prevalence and Predictors of Hair Shedding Among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia

    January 2026 in “ Skin Appendage Disorders
    Sali Alharbi, Azzam Alkhalifah
    A recent cross-sectional study from Saudi Arabia found that hair shedding affects 70% of GLP-1 receptor agonist users, a prevalence ten times higher than reported in registration trials. This issue notably impacts treatment adherence, especially in women experiencing significant weight loss. The study highlights the importance of proactive counseling and nutritional optimization to support continued treatment adherence.
    Discuss this study in the Community →

    Research cited in this study

    11 / 11 results

    Related Community Posts Join

    6 / 1000+ results

      community Female, 30, PCOS diagnosis, MPB Norwood 2. Endo refuses to give anything other than Spironolactone. Feel like I’m at my wit’s end here.

      in Female  55 upvotes 2 years ago
      A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

      community He used Dutasteride for 20 years. Interview

      in Treatment  111 upvotes 1 year ago
      Dutasteride has been used for 20 years with some hair thickness improvement but no dramatic regrowth. The user also experimented with minoxidil, tretinoin, and peptides like BPC 157 for potential benefits in hair density and quality.

      community PP405 Phase 2a press release with early results

      in Research/Science  700 upvotes 8 months ago
      PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

      community Story time! The Great Unbalding (PP405)

      in Research/Science  232 upvotes 4 months ago
      PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

    Similar Research

    5 / 1000+ results